These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 27349985)

  • 1. The role of phenotypic plasticity in the escape of cancer cells from targeted therapy.
    Emmons MF; Faião-Flores F; Smalley KSM
    Biochem Pharmacol; 2016 Dec; 122():1-9. PubMed ID: 27349985
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epithelial Mesenchymal Transition in Aggressive Lung Cancers.
    Mittal V
    Adv Exp Med Biol; 2016; 890():37-56. PubMed ID: 26703798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRAF inhibitors in cancer therapy.
    Hertzman Johansson C; Egyhazi Brage S
    Pharmacol Ther; 2014 May; 142(2):176-82. PubMed ID: 24325952
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BRAF, a target in melanoma: implications for solid tumor drug development.
    Flaherty KT; McArthur G
    Cancer; 2010 Nov; 116(21):4902-13. PubMed ID: 20629085
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming resistance to molecularly targeted anticancer therapies: Rational drug combinations based on EGFR and MAPK inhibition for solid tumours and haematologic malignancies.
    Tortora G; Bianco R; Daniele G; Ciardiello F; McCubrey JA; Ricciardi MR; Ciuffreda L; Cognetti F; Tafuri A; Milella M
    Drug Resist Updat; 2007 Jun; 10(3):81-100. PubMed ID: 17482503
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel therapeutic strategies for patients with NSCLC that do not respond to treatment with EGFR inhibitors.
    Rolfo C; Giovannetti E; Hong DS; Bivona T; Raez LE; Bronte G; Buffoni L; Reguart N; Santos ES; Germonpre P; Taron M; Passiglia F; Van Meerbeeck JP; Russo A; Peeters M; Gil-Bazo I; Pauwels P; Rosell R
    Cancer Treat Rev; 2014 Sep; 40(8):990-1004. PubMed ID: 24953979
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting BRAF in melanoma: biological and clinical challenges.
    Mandalà M; Voit C
    Crit Rev Oncol Hematol; 2013 Sep; 87(3):239-55. PubMed ID: 23415641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The great escape: tumour cell plasticity in resistance to targeted therapy.
    Boumahdi S; de Sauvage FJ
    Nat Rev Drug Discov; 2020 Jan; 19(1):39-56. PubMed ID: 31601994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
    Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
    Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epithelial-to-mesenchymal plasticity of cancer stem cells: therapeutic targets in hepatocellular carcinoma.
    Jayachandran A; Dhungel B; Steel JC
    J Hematol Oncol; 2016 Aug; 9(1):74. PubMed ID: 27578206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting EMT in cancer: opportunities for pharmacological intervention.
    Davis FM; Stewart TA; Thompson EW; Monteith GR
    Trends Pharmacol Sci; 2014 Sep; 35(9):479-88. PubMed ID: 25042456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy.
    Kemper K; de Goeje PL; Peeper DS; van Amerongen R
    Cancer Res; 2014 Nov; 74(21):5937-41. PubMed ID: 25320006
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy of melanoma using kinase inhibitors.
    Heppt MV; Tietze JK; Graf SA; Berking C
    Curr Opin Oncol; 2015 Mar; 27(2):134-40. PubMed ID: 25602684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Target cell movement in tumor and cardiovascular diseases based on the epithelial-mesenchymal transition concept.
    Chua KN; Poon KL; Lim J; Sim WJ; Huang RY; Thiery JP
    Adv Drug Deliv Rev; 2011 Jul; 63(8):558-67. PubMed ID: 21335038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types.
    Britten CD
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1395-409. PubMed ID: 23443307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibroblast-mediated drug resistance in cancer.
    Paraiso KH; Smalley KS
    Biochem Pharmacol; 2013 Apr; 85(8):1033-41. PubMed ID: 23376122
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
    Abdollahi A; Folkman J
    Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.